We recommend you visit the ZikaInfection hub to access all the tools and resources. |
September 13, 2021 - Since the end of 2019, the world has faced an exceptional epidemiological situation characterized by the widespread transmission of SARS CoV-2 and the high number of cases and deaths from COVID-19. Despite this serious emergency, it ... Read more
April 27, 2021 - As the ZikaPLAN project ends, a new series of films highlight the stories behind this international consortium, from the people and communities affected by Zika, to the pioneering scientific studies that underpinned our work, through to ... Read more
Resources include high-level justification for why engagement is important in an epidemic situation, as well as practical guides and tools on how to implement engagement activities in these circumstances. Read more
April 30, 2021 - Where there’s a will there’s a way: in a healthier global climate, we would have marked the culmination of almost five years of extraordinary work with a collective gathering in France, to share milestones and achievements. ... Read more
Nowshin Papri et al. - Nature Reviews Neurology, March 1, 2021
In this review, the authors report that Guillain-Barré syndrome (GBS) is an under-reported disease in low- and middle-income countries (LMIC). They highlight the most important knowledge gaps and provide suggestions and recommendations for future research.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.Read more
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques. Read more
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE). Read more
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.